Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AstraZeneca has presented new data from its pipeline of investigational cancer medicines at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid. Together with MedImmune, its global...
-
Moventig® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation AstraZeneca today announced that the Committee for Medicinal Products for...
-
FDA APPROVES MOVANTIK™ (naloxegol) TABLETS C-II FOR THE TREATMENT OF OPIOID -INDUCED CONSTIPATION IN ADULT PATIENTS WITH CHRONIC NON-CANCER PAIN AstraZeneca today announced that the US Food and Drug...
-
ASTRAZENECA AND LILLY ANNOUNCE ALLIANCE TO DEVELOP AND COMMERCIALISE BACE INHIBITOR AZD3293 FOR ALZHEIMER'S DISEASE AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement...
-
Transactions by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 1 September 2014, Luke Miels, EVP, Global Product and Portfolio Strategy, a person discharging managerial...
-
På ESC presenteras idag resultaten från observationsstudien APOLLO, som belyser de långsiktiga riskerna för nya hjärt- och kärlhändelser eller dödsfall bland patienter som överlevt i minst ett år...
-
Behandlingsresultaten vid kroniskt obstruktiv lungsjukdom har kraftigt förbättrats det senaste decenniet. En ny omfattande studie visar att det är mycket tack vare sjuksköterskors och läkares...
-
UNITED STATES DEPARTMENT OF JUSTICE CLOSES INVESTIGATION INTO PLATO CLINICAL TRIAL FOR BRILINTA AstraZeneca today announced that it has received confirmation from the United States Department of...
-
ASTRAZENECA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE PHASE III PROGRAMME OF CAZ-AVI IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS (cIAI) CAZ-AVI treated patients with cIAI as...
-
AstraZeneca today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the...